URT Urteste S.A.
Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Urteste (WSE: URT)
›
Urteste (WSE: URT) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 37 employees.
The shares were at 52.00 PLN on 19 November 2026, up 4.0% over 52 weeks. Its 52-week range is 24.00 PLN to 72.20 PLN: the price is 28.0% below the high and 116.7% above the low.
Its market capitalisation is 79.36M PLN.
Urteste reports return on equity of -24.0%, an operating margin of -125.0% and revenue up 55.7% year over year.
It holds more cash than debt, a net cash position of 588.00K PLN. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.